AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02801721 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: psycho social stimulation
Description: The psychosocial intervention lasted for 9 months and included play demonstrations at home by a play leader (PL) who was trained to visit homes and teach the mothers about child development and care practices. They also showed the mothers how to play with children using toys in a way to promote good child development. In the original study all anemic children in early childhood received 30 mg ferrous sulphate daily based on recommendations from both the WHO (2003) and IOM reports (2001) for 6 months.
Study NCT04096820 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Uromune
Description: 2 sprays of vaccine under the tongue for 90 days. Liquid is to held under tongue for 2 minutes without swallowing.
Study NCT03847454 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care for rehabilitation treatment for musculoskeletal patients.
Study NCT04398173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: multiparametric MRI
Description: T1-w, T2-w, diffusion weighted and dynamic contrast-enhanced imaging
Study NCT04318834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tumour and germline molecular profiling
Description: Tumour whole genome sequencing, germline whole genome sequencing, tumour whole transcriptome sequencing
Study NCT03898505 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AvoMax (Low Dose)
Description: AvoMax (Low Dose) is a natural spray-dried avocado powder, which contains 50 mg of a combination of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene.
Study NCT03898505 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AvoMax (High Dose)
Description: AvoMax (High Dose) is a natural spray-dried avocado powder, which contains a total of 200 mg of a combination of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene.
Study NCT03898505 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product is powder containing only non-medicinal ingredients used in the test product: Oryza sativa (rice) bran extract (65-70% w/w of total placebo formulation), sodium bicarbonate, rosemary extract, xylitol, silicon dioxide, microcrystalline cellulose, rice hull powder, strawberry flavour.
Study NCT03674515 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Smartphone application placebo
Description: Strategy based on smartphone application placebo
Study NCT03674515 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone equipped with application bouge = Coach group
Description: Strategy based on smartphone application bouge
Study NCT00974805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide 500 Accuhaler
Description: Seretide 500 accuhaler one inhalation BD
Study NCT01939288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular stimulation, followed by intermittent pneumatic compression
Study NCT01939288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression, followed by neuromuscular stimulation
Study NCT01065623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY79-4620
Description: 1-hour infusion every 14 days. Starting dose will be 0.15 mg/ kg and dose will be escalated dependent on any dose limiting toxicities
Study NCT02062918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal belt
Study NCT04007094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ViviGen Cellular Bone Matrix
Description: ViviGen Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 1271.10
Study NCT01000441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infliximab, etanercept, adalimumab
Study NCT01000441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abatacept, rituximab or tocilizumab
Study NCT04147221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem-relebactam
Description: After receipt of imipenem-relebactam, participants will have six blood samples collected over 6 hours for determination of imipenem and relebactam concentrations.
Study NCT03968484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet transfusion
Description: Transfusion of platelets
Study NCT02279719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Description: BBI608 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
Study NCT02279719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI503
Description: BBI503 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
Study NCT02279719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.
Study NCT02279719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.
Study NCT01360398 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample
Description: Blood samples will be collected from all patients at enrolment, at follow-up visits, at exacerbation visits, and during the final visit.
Study NCT01360398 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sputum sample
Description: Sputum will be collected from all patients at enrolment, at monthly follow-up visits, at exacerbation visits, and during the final visit. Sputum will be obtained by spontaneous expectoration or induced by stimulation according to standard methods.
Study NCT01360398 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nasopharyngeal swab
Description: Nasopharyngeal swabs will be collected from all patients at enrolment and from a subcohort of 30 patients at monthly follow-up visits and at exacerbation visits during the first year.
Study NCT01360398 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Urine sample
Description: Urine samples will be taken at enrolment and exacerbation visits from all subjects and from the same subcohort of 30 patients providing nasopharyngeal swabs, at monthly follow-up visits during the first year.
Study NCT01360398 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: End tidal breath sample
Description: Breath samples will be collected from all patients at enrolment, at follow-up visits (monthly), at exacerbation visits, and during the final visit.
Study NCT01360398 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Data collection
Description: Patient interview, diary cards review and questionnaires completion
Study NCT01360398 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tests
Description: Urine pregnancy test, chest CT-scan, lung function testing and 6-min walk test
Study NCT03155334 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PIS User Testing
Description: PIS User Testing based on an iterative 4-step process in a cohort of participants (the target group):~* individual reading of the text;~* individual questionnaire for a quantitative and qualitative evaluation;~* a brief semi-structured interview to each participant;~* a text revision to address any problems identified from participant feedback.
Study NCT03461731 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 800 nm laser
Description: 800 nm laser applied to forearm at 4.4 Joules per square cm during 40 hand grips
Study NCT03461731 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: combination laser
Description: 800 nm and 905 nm laser applied to forearm at 4.4 Joules per square cm during 40 hand grips
Study NCT03461731 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 905 nm laser
Description: 905 nm laser applied to forearm at 4.4 Joules per square cm during 40 hand grips
Study NCT03481036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Direct Acting Antivirals
Description: Sofosbuvir and Daclatasvir
Study NCT03481036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAAs in Cirrhotics Genotype 2/3
Description: Sofosbuvir and Daclatasvir with weight based ribavirin
Study NCT03481036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAAs in Cirrhotics Genotye 1,4,5,6
Description: Sofosbuvir and Ledipasvir with weight based ribavirin
Study NCT00540514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel
Description: Administered by intravenous infusion.
Study NCT00540514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered by intravenous infusion.
Study NCT00540514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered by intravenous infusion. Dosing was based on the Calvert formula: carboplatin dose (mg) = (Target AUC) x (glomerular filtration rate \[GFR\] + 25). For the purposes of this protocol, the GFR is considered to be equivalent to creatinine clearance (calculated by the method of Cockcroft and Gault, 1976).
Study NCT00540514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered by intravenous infusion. Dosing was based on the Calvert formula: carboplatin dose (mg) = (Target AUC) x (glomerular filtration rate \[GFR\] + 25). For the purposes of this protocol, the GFR is considered to be equivalent to creatinine clearance (calculated by the method of Cockcroft and Gault, 1976).
Study NCT01740986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA09012 Low dose
Description: Tablet, b.i.d
Study NCT01740986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA09012 High dose
Description: Tablet, b.i.d
Study NCT01740986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, b.i.d
Study NCT04012385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle counseling
Description: Nutritional plan and Physical activity goals
Study NCT02625272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A
Description: The novel hand-assisted laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer. In this group, greater omentum, transverse colon, and ileum were brought out through the hand-port incision at the beginning of the operation and divided extracorporeally.
Study NCT02656121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 6000 IU of vitamin D3
Study NCT02656121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovulatory Agent
Description: only Clomophine Citrate
Study NCT02656121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ovulatory Agent
Description: only Clomophine Citrate
Study NCT00516893 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG00002-E (natalizumab high titer)
Study NCT01925495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: varied middle-ear pressure
Study NCT01925495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varied middle-ear gas composition
Study NCT01925495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: varied ear-canal pressure
Study NCT00355537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Sustanon- intramuscular testosterone 200mg every 2 weeks
Study NCT00355537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: Saline injection intramuscular every 2 weeks
Study NCT01428037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet vaginal inserted at 4 hrly interval with maximum of three doses
Study NCT01428037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol vaginal Tablet 25 mcg
Description: One tablet vaginal insert at 4 hrly interval with maximum of three doses
Study NCT00728208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK372475
Description: 1.5mg for 28 days
Study NCT01144975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XOMA 052
Description: Sterile solution, dose level varies by dose group and study drug administration day, SC injections administered by study personnel at time points specified in the protocol (the subject will receive a total of 8 injections)
Study NCT01144975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile solution, SC injections administered by study personnel (the subject will receive a total of 8 injections)
Study NCT04014881 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Third-generation anti-CD123 CAR-T cells
Description: From the minimum dose, If no DLT emerges in the group, then the next group uses the subsequent higher dose. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level.
Study NCT01941979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU, Capecitabine, Oxaliplatin, Leucovorin.
Study NCT00583414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair
Description: Endovascular exclusion of aneurysm
Study NCT06326619 — intervention group
Intervention type: PROCEDURE
Intervention: Primary tumor resection
Description: In addition to systemic therapy a primary tumor resection was performed.
Study NCT06326619 — intervention group
Intervention type: PROCEDURE
Intervention: Systemic Therapy
Description: chemotherapy, antibody, or immunotherapy (alone or in combination) starting within 12 months after diagnosis
Study NCT00814697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Coil Stimulation (rTMS)
Description: The first six patients were administered rTMS at 10Hz in 20 trains of 5 seconds with 20 second intervals between trains in each hemisphere. The total number of pulses for each session was set at 1000 pulses. The second six enrolled patients were administered rTMS at 15 Hz in 20 trains of 5 seconds with 25 second intervals between trains in each hemisphere.
Study NCT00002938 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional surgery
Description: Salvage prostatectomy
Study NCT02419196 — intervention group
Intervention type: OTHER
Intervention: Perioperative pulmonary function tests
Description: Pulmonary electrical impedance tomography, spirometry, pulse oximetry and query performed preoperatively, at the first and the third postoperative day
Study NCT02795507 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabit-Tec System
Description: Device with visual and kinesthetic feedback
Study NCT02795507 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rehabit-Tec System
Description: Device without visual and kinesthetic feedback
Study NCT02795507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: conventional exercises
Study NCT02795507 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional exercises
Study NCT00731653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Product: BCI-024 + BCI-049
Description: BCI-024 and BCI-049 once a day at bedtime for 6 weeks
Study NCT04465032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gut microbiome transplantation
Description: Fecal transplantation will be performed at baseline and at week 3 and 6. At the Department of Clinical Bacteriology either the autologous or allogenic feces is prepared for donation by an experienced lab co-worker. The fecal transplantation will be performed via gastroduodenal endoscopy at the Department of Gastroenterology by an experienced endoscopist. To alleviate the procedure, midazolam is offered to the participants. Following placement of the endoscope in the horizontal duodenum, 150 mL feces solution is inserted via the endoscope.
Study NCT04465032 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gut microbiome transplantation
Description: Fecal transplantation will be performed at baseline and at week 3 and 6. At the Department of Clinical Bacteriology either the autologous or allogenic feces is prepared for donation by an experienced lab co-worker. The fecal transplantation will be performed via gastroduodenal endoscopy at the Department of Gastroenterology by an experienced endoscopist. To alleviate the procedure, midazolam is offered to the participants. Following placement of the endoscope in the horizontal duodenum, 150 mL feces solution is inserted via the endoscope.
Study NCT03788018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine and dexmedetomidine IV
Description: Patients received IV bolus infusion of lidocaine (2%) 1.5 mg/kg and dexmedetomidine 0.5 µg/kg diluted with normal saline to 20 ml in the LD group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion at rate of lidocaine 1.5 mg/kg and dexmedetomidine 0.4 µg/kg made up to 20 mL every hour until 30 min before the end of operation, respectively.
Study NCT03788018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline IV
Description: Patients received 20 ml normal saline and 20 ml normal saline in the CON group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion 20 ml normal saline and 20 ml normal saline every hour until 30 min before the end of surgery
Study NCT04509518 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise therapy program plus TENS therapy
Description: All patients were receiving the same physical therapy exercise program, 3 times per week for 12 weeks in the form of pelvic floor relaxation exercises, diastasis correction exercises , myofascial trigger points release, connective tissue manipulation and progressive abdominal strengthening exercises. Pelvic floor relaxation exercises included pelvic floor release stretches, Proprioceptive Neuromuscular Facilitation technique, and pelvic floor drop exercises in addition to TENS therapy The standard protocol for TENS therapy in this group was 20 minutes of 100 Hz frequency, pulse duration of 200 µsec, three times a week for successive 12 weeks
Study NCT04509518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy program plus TENS therapy
Description: All patients were receiving the same physical therapy exercise program, 3 times per week for 12 weeks in the form of pelvic floor relaxation exercises, diastasis correction exercises , myofascial trigger points release, connective tissue manipulation and progressive abdominal strengthening exercises. Pelvic floor relaxation exercises included pelvic floor release stretches, Proprioceptive Neuromuscular Facilitation technique, and pelvic floor drop exercises in addition to TENS therapy The standard protocol for TENS therapy in this group was 20 minutes of 100 Hz frequency, pulse duration of 200 µsec, three times a week for successive 12 weeks
Study NCT00301600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: MMF,1.0g/d
Study NCT01468207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous injection
Study NCT01468207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo pre-filled syringe, administered by subcutaneous injection
Study NCT01468207 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo pre-filled syringe, administered by subcutaneous injection
Study NCT01713361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS-FXIRx Dose #2
Description: Group B: ISIS-FXIRx dose #2 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
Study NCT01713361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS-FXIRx Dose #3
Description: Group C: ISIS-FXIRx dose #3 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
Study NCT01713361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin (40mg) will be administered by subcutaneous injection the evening prior to total knee arthroplasty (optionally), 6 to 8 hours after surgery, followed by daily injections for at least 8 additional days post surgery (a total of at least 9 consecutive days). \[Except for Canadian region, in which the subcutaneous injection of enoxaparin the evening prior to total knee arthroplasty is expected, resulting in a total of at least 10 consecutive days of enoxaparin.\]
Study NCT01225965 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ectoin Inhalation Solution
Description: Once daily inhalation of Ectoin Inhalation Solution
Study NCT01225965 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily inhalation of Placebo Inhalation Solution
Study NCT01938508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: minocycline hydrochloride capsules in microgranules equivalent to 100 mg of minocycline